Helen MacDonald

But that's one chunk of information there that's the shared decision aids.

The other thing is that if you wanted to take this and work out what you should do in your organisation, the way that the data are structured,

on the Magic App means that you can download and sort of localise that information.

There are ways that you can make it flow into your electronic healthcare record and do all kinds of clever things that I don't fully understand.

But if you are an organisation out there interested in using the information, you should definitely get in touch.

And you think that might be untrue?

So how do you think it plays out?

Or just don't use it.

Help the environment as well.

So I've got something I wanted to talk about this week.

I think it's something of an EBM bombshell, actually.

So, Carl, brace yourself.

There are two papers recently published on BMJ, one research paper and one analysis paper, which I found very intriguing.

And I'm going to hone my inner sensationism to say that, in effect, we appear to have published a study that says that blinding doesn't really matter in trials.

That's not quite true.

But I guess that's headline now I've retracted it.

But so blinding is the idea that if participants and those caring for them and assessing their outcomes, if they don't know which treatment they're in in trials, that's a good thing.

It reduces bias and sort of evens out expectations and placebo and placebo effects.

And it's the gold standard.

And everyone knows that it's always a good thing.